Related Experiment Video
Updated: Jul 18, 2026

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype
Published on: March 18, 2020
T cell-directed therapies: lessons learned and future prospects
Eric H Liu1, Richard M Siegel, David M Harlan
1Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892, USA.
Abstract:
Agents interfering with T cell function are therapeutic mainstays for various autoimmune diseases and for transplant approaches to organ failure. The understanding of T cell biology has blossomed since the development of most agents now in use. Here we discuss T cell-specific agents now in use, others recently added to the therapeutic armamentarium and promising agents being investigated in clinical and preclinical studies. In addition, we reflect on the risks and benefits involved in the testing of such agents clinically, with examples of agents that have successfully been used in the clinic and agents that failed to reach therapeutic use.
Insights
Agents targeting T cell function are crucial for autoimmune diseases and transplants. This review covers current, new, and investigational T cell therapies, discussing their clinical risks and benefits.
Area of Science:
- Immunology
- Pharmacology
- Transplantation
Background:
- T cell-targeting agents are foundational in treating autoimmune diseases and organ transplant rejection.
- Advances in T cell biology have significantly informed the development of these therapies.
- Current therapeutic strategies rely heavily on modulating T cell activity.
Purpose of the Study:
- To review existing, recently approved, and investigational T cell-specific agents.
- To analyze the clinical risks and benefits associated with these immunomodulatory therapies.
- To provide examples of successful and unsuccessful clinical applications of T cell-targeting drugs.
Main Methods:
- Literature review of T cell-specific agents in clinical and preclinical development.
- Analysis of clinical trial data and published outcomes for immunomodulatory drugs.
- Comparative assessment of therapeutic efficacy and safety profiles.
Main Results:
- Identified a range of T cell-modulating agents currently in use and under investigation.
- Highlighted the evolving landscape of immunotherapies for autoimmune conditions and transplantation.
- Documented instances where clinical translation of T cell agents succeeded and where it faced challenges.
Conclusions:
- The development of T cell-specific agents continues to advance, offering new hope for complex diseases.
- Careful evaluation of risks versus benefits is paramount for the clinical success of these potent immunomodulators.
- Ongoing research is crucial for optimizing T cell-based therapies and expanding their therapeutic applications.
Related Concept Videos
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Cell-mediated Immune Responses
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Microorganisms in Medicine and Therapeutics

